Literature DB >> 23623823

Recent advances in quantitative neuroproteomics.

George E Craft1, Anshu Chen, Angus C Nairn.   

Abstract

The field of proteomics is undergoing rapid development in a number of different areas including improvements in mass spectrometric platforms, peptide identification algorithms and bioinformatics. In particular, new and/or improved approaches have established robust methods that not only allow for in-depth and accurate peptide and protein identification and modification, but also allow for sensitive measurement of relative or absolute quantitation. These methods are beginning to be applied to the area of neuroproteomics, but the central nervous system poses many specific challenges in terms of quantitative proteomics, given the large number of different neuronal cell types that are intermixed and that exhibit distinct patterns of gene and protein expression. This review highlights the recent advances that have been made in quantitative neuroproteomics, with a focus on work published over the last five years that applies emerging methods to normal brain function as well as to various neuropsychiatric disorders including schizophrenia and drug addiction as well as of neurodegenerative diseases including Parkinson's disease and Alzheimer's disease. While older methods such as two-dimensional polyacrylamide electrophoresis continued to be used, a variety of more in-depth MS-based approaches including both label (ICAT, iTRAQ, TMT, SILAC, SILAM), label-free (label-free, MRM, SWATH) and absolute quantification methods, are rapidly being applied to neurobiological investigations of normal and diseased brain tissue as well as of cerebrospinal fluid (CSF). While the biological implications of many of these studies remain to be clearly established, that there is a clear need for standardization of experimental design and data analysis, and that the analysis of protein changes in specific neuronal cell types in the central nervous system remains a serious challenge, it appears that the quality and depth of the more recent quantitative proteomics studies is beginning to shed light on a number of aspects of neuroscience that relates to normal brain function as well as of the changes in protein expression and regulation that occurs in neuropsychiatric and neurodegenerative disorders.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23623823      PMCID: PMC3891841          DOI: 10.1016/j.ymeth.2013.04.008

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  347 in total

Review 1.  Neuroproteomics of the synapse and drug addiction.

Authors:  Noura S Abul-Husn; Lakshmi A Devi
Journal:  J Pharmacol Exp Ther       Date:  2006-04-27       Impact factor: 4.030

2.  Alterations in protein regulators of neurodevelopment in the cerebrospinal fluid of infants with posthemorrhagic hydrocephalus of prematurity.

Authors:  Diego M Morales; R Reid Townsend; James P Malone; Carissa A Ewersmann; Elizabeth M Macy; Terrie E Inder; David D Limbrick
Journal:  Mol Cell Proteomics       Date:  2011-12-20       Impact factor: 5.911

3.  Stable isotope labeling with amino acids in cell culture-based proteomic analysis of ethanol-induced protein expression profiles in microglia.

Authors:  Bin Liu; David S Barber; Stanley M Stevens
Journal:  Methods Mol Biol       Date:  2012

4.  Clozapine treatment causes oxidation of proteins involved in energy metabolism in lymphoblastoid cells: a possible mechanism for antipsychotic-induced metabolic alterations.

Authors:  Muhammad R Baig; Erica Navaira; Michael A Escamilla; Henriette Raventos; Consuelo Walss-Bass
Journal:  J Psychiatr Pract       Date:  2010-09       Impact factor: 1.325

Review 5.  Mass spectrometry imaging and profiling of single cells.

Authors:  Eric J Lanni; Stanislav S Rubakhin; Jonathan V Sweedler
Journal:  J Proteomics       Date:  2012-03-29       Impact factor: 4.044

6.  Quantitative peptidomics for discovery of circadian-related peptides from the rat suprachiasmatic nucleus.

Authors:  Ji Eun Lee; Leonid Zamdborg; Bruce R Southey; Norman Atkins; Jennifer W Mitchell; Mingxi Li; Martha U Gillette; Neil L Kelleher; Jonathan V Sweedler
Journal:  J Proteome Res       Date:  2013-01-11       Impact factor: 4.466

7.  Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice.

Authors:  Lujian Liao; Sung Kyu Park; Tao Xu; Peter Vanderklish; John R Yates
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-30       Impact factor: 11.205

8.  Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex.

Authors:  Dan Ma; Man K Chan; Helen E Lockstone; Sandra R Pietsch; Declan N C Jones; Jackie Cilia; Mark D Hill; Melanie J Robbins; Isabel M Benzel; Yagnesh Umrania; Paul C Guest; Yishai Levin; Peter R Maycox; Sabine Bahn
Journal:  J Proteome Res       Date:  2009-07       Impact factor: 4.466

9.  Combining comparative proteomics and molecular genetics uncovers regulators of synaptic and axonal stability and degeneration in vivo.

Authors:  Thomas M Wishart; Timothy M Rooney; Douglas J Lamont; Ann K Wright; A Jennifer Morton; Mandy Jackson; Marc R Freeman; Thomas H Gillingwater
Journal:  PLoS Genet       Date:  2012-08-30       Impact factor: 5.917

10.  Peptidome analysis of cerebrospinal fluid by LC-MALDI MS.

Authors:  Mikko Hölttä; Henrik Zetterberg; Ekaterina Mirgorodskaya; Niklas Mattsson; Kaj Blennow; Johan Gobom
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

View more
  40 in total

1.  Mass spectrometric analysis of rat cerebrospinal fluid proteins following exposure to the neurotoxicant carbonyl sulfide.

Authors:  O Lardinois; P J Kirby; D L Morgan; R C Sills; K B Tomer; L J Deterding
Journal:  Rapid Commun Mass Spectrom       Date:  2014-12-15       Impact factor: 2.419

2.  Proteomic biomarkers for brain disorders: technical considerations and challenges.

Authors:  Linda S Brady; William Z Potter
Journal:  Neuropsychopharmacology       Date:  2014-01       Impact factor: 7.853

Review 3.  Quantitative proteomic analysis of histone modifications.

Authors:  He Huang; Shu Lin; Benjamin A Garcia; Yingming Zhao
Journal:  Chem Rev       Date:  2015-02-17       Impact factor: 60.622

Review 4.  Counting numbers of synaptic proteins: absolute quantification and single molecule imaging techniques.

Authors:  Angela Patrizio; Christian G Specht
Journal:  Neurophotonics       Date:  2016-06-03       Impact factor: 3.593

Review 5.  What Have Mass Spectrometry-Based Proteomics and Metabolomics (Not) Taught Us about Psychiatric Disorders?

Authors:  Christoph W Turck; Michaela D Filiou
Journal:  Mol Neuropsychiatry       Date:  2015-05-12

Review 6.  Decoding neuroproteomics: integrating the genome, translatome and functional anatomy.

Authors:  Robert R Kitchen; Joel S Rozowsky; Mark B Gerstein; Angus C Nairn
Journal:  Nat Neurosci       Date:  2014-10-28       Impact factor: 24.884

Review 7.  Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions.

Authors:  Anubhuti Dixit; Rachna Mehta; Abhishek Kumar Singh
Journal:  Cell Mol Neurobiol       Date:  2019-06-12       Impact factor: 5.046

8.  Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model.

Authors:  Caroline E Germany; Ashlie N Reker; David J Hinton; Alfredo Oliveros; Xinggui Shen; Lindsey G Andres-Beck; Katheryn M Wininger; Marjan Trutschl; Urska Cvek; Doo-Sup Choi; Hyung W Nam
Journal:  Proteomics       Date:  2018-04       Impact factor: 3.984

Review 9.  Peptidomics for the discovery and characterization of neuropeptides and hormones.

Authors:  Elena V Romanova; Jonathan V Sweedler
Journal:  Trends Pharmacol Sci       Date:  2015-07-01       Impact factor: 14.819

10.  Chronic exposure to light reverses the effect of maternal separation on proteins in the prefrontal cortex.

Authors:  J J Dimatelis; D J Stein; V A Russell
Journal:  J Mol Neurosci       Date:  2013-07-25       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.